Skip to content
10-Q

Quarterly Report

ENTRADA THERAPEUTICS, INC. TRDA

0001689375-25-000024

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 37.95M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $67.84M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $101.21M
Current Liabilities Q1 2025 · Mar 31, 2025 $18.43M
Current Liabilities Q1 2025 · Dec 31, 2024 $39.48M
Total Liabilities Q1 2025 · Mar 31, 2025 $69.22M
Total Liabilities Q1 2025 · Dec 31, 2024 $97.64M
Current Assets Q1 2025 · Mar 31, 2025 $403.19M
Current Assets Q1 2025 · Dec 31, 2024 $440.04M
Total Assets Q1 2025 · Mar 31, 2025 $486.48M
Total Assets Q1 2025 · Dec 31, 2024 $526.32M
Shares Diluted Q1 2025 · Mar 31, 2024 34.79M sh
Capex Q1 2025 · Mar 31, 2024 $838K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$25.52M
Stockholders Equity Q1 2025 · Mar 31, 2024 $269.37M
Stockholders Equity Q1 2025 · Dec 31, 2023 $242.36M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.68
Eps Basic Q1 2025 · Mar 31, 2024 $0.70
Sga Expense Q1 2025 · Mar 31, 2024 $9.4M
Rd Expense Q1 2025 · Mar 31, 2024 $28.61M
Net Income Q1 2025 · Mar 31, 2024 $23.5M
Operating Income Q1 2025 · Mar 31, 2024 $21.11M
Revenue Q1 2025 · Mar 31, 2024 $59.12M